Commentary: CD6 As a Potential Target for Treating Multiple Sclerosis
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Alternative Splicing of Pre-mRNA in the Control of Immune Activity.
Su Z, Huang D Genes (Basel). 2021; 12(4).
PMID: 33921058 PMC: 8071365. DOI: 10.3390/genes12040574.
Multifaceted effects of soluble human CD6 in experimental cancer models.
Simoes I, Aranda F, Casado-Llombart S, Velasco-de Andres M, Catala C, Alvarez P J Immunother Cancer. 2020; 8(1).
PMID: 32217757 PMC: 7174071. DOI: 10.1136/jitc-2019-000172.
References
1.
Santos R, Oliveira L, Carmo A
. Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses. Curr Drug Targets. 2015; 17(6):630-9.
DOI: 10.2174/1389450116666150531152439.
View
2.
Hernandez P, Moreno E, Aira L, Rodriguez P
. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab. Curr Drug Targets. 2016; 17(6):666-77.
DOI: 10.2174/1389450117666160201114308.
View
3.
Chatenoud L
. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications. Curr Opin Immunol. 2005; 17(6):632-7.
DOI: 10.1016/j.coi.2005.09.011.
View
4.
Kofler D, Farkas A, von Bergwelt-Baildon M, Hafler D
. The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations. Curr Drug Targets. 2016; 17(6):651-65.
DOI: 10.2174/1389450117666160201105934.
View
5.
Singer N, Mitra R, Lialios F, Richardson B, Marks R, Pesando J
. CD6 dependent interactions of T cells and keratinocytes: functional evidence for a second CD6 ligand on gamma-interferon activated keratinocytes. Immunol Lett. 1997; 58(1):9-14.
DOI: 10.1016/s0165-2478(97)02707-7.
View